ZimVie, a global leader in dental implants, has announced a definitive agreement to be acquired by an affiliate of ARCHIMED, a healthcare investment firm.
Under the agreement, ZimVie shareholders will receive $19 in cash per share, valuing the company at approximately $730 million and offering a 99% premium over its 90-day volume-weighted average price of $9.57.
The deal, approved unanimously by ZimVie’s Board of Directors, is expected to close by the end of 2025, subject to customary shareholder and regulatory approvals. ZimVie will continue its operations separately until the transaction is finalized and will be delisted from NASDAQ once it is private.
Advisors: Centerview Partners serves as the exclusive financial advisor to ZimVie, and Cravath, Swaine & Moore LLP serves as the legal advisor. And UBS Investment Bank is serving as the exclusive financial advisor to ARCHIMED, and Latham & Watkins LLP is serving as the legal advisor.
KEY QUOTES:
“This transaction marks a new chapter for ZimVie and underscores the value our team has built over the past several years. Partnering with ARCHIMED will create value for our shareholders while providing the strategic and financial backing to expand our innovative dental technology to more patients globally.”
Vafa Jamali, Chairman of the Board and Chief Executive Officer of ZimVie
“We’re excited to partner with ZimVie and its talented team. The company has strong fundamentals and compelling growth potential, and we look forward to supporting its next chapter.”
André-Michel Ballester, Managing Partner, at ARCHIMED
